Howard Liang, Ph.D.

Managing Director, Biotechnology

Howard Liang joined the biotech team as a Director in 2005 covering biotech companies with an oncology focus. Dr. Liang came to Leerink Swann from A.G. Edwards where he was a senior biotechnology analyst. His prior Wall St. experience includes JMP Securities as a senior biotechnology analyst and Prudential Securities, where he was an associate to an Institutional Investor-ranked major pharma analyst. Before that, he spent eight years at Abbott Laboratories where he was a senior scientist and a member of one of the industry's leading structure-based drug discovery teams. During his career as a scientist, Dr. Liang authored papers in prestigious journals including Nature, Science, and Proceedings of the National Academy of Sciences. Dr. Liang obtained his MBA and Ph.D. in Biochemistry and Molecular biology, both from the University of Chicago. His undergraduate degree is a B.S. in chemistry from Beijing University.